Evgen Pharma (TCF) AI Stock Analysis

• Market Cap: £4.51M
• Dividend Yield: N/A
• Average Volume (3M): 1.69M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.98
• Revenue Growth: N/A
• EPS Growth: 85.56%
• Country: UK
• Employees: 9
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 2,148,963,600
• 10 Day Avg. Volume: 2,190,584
• 30 Day Avg. Volume: 1,685,058
• PEG Ratio: <0.01
• Price to Book (P/B): 0.20
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.51
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: 0.20p ▼(-2.50% Downside)

The score is held down primarily by weak financial performance (ongoing losses and persistent cash burn) and bearish technicals (price below key moving averages with negative MACD). Positive corporate milestones provide some offset, but valuation signals are limited due to negative earnings and no dividend support.

Positive Factors

Strong Equity Position

A strong equity position with no debt provides financial stability and flexibility, allowing the company to invest in R&D and strategic initiatives without the burden of interest payments.

Strategic Board Appointments

Strategic board appointments can enhance leadership quality and provide new insights, potentially improving strategic direction and operational execution, which is crucial for long-term growth.

Successful Fundraising

Successful fundraising extends the cash runway, enabling the company to reach key development milestones and potentially unlock commercial opportunities, crucial for sustaining operations and growth.

Negative Factors

Declining Revenue

Declining revenue indicates challenges in market penetration and product adoption, which can hinder long-term growth and profitability if not addressed.

Negative Cash Flow

Negative cash flow suggests ongoing cash burn, which can strain resources and limit the ability to invest in growth opportunities, impacting long-term sustainability.

Consistent Losses

Consistent losses highlight operational inefficiencies and profitability challenges, which can undermine financial health and investor confidence over time if not rectified.

Evgen Pharma Business Overview & Revenue Model

Company Description

Theracryf Plc, a clinical stage therapeutics company, engages in the development of therapeutics for oncology and behavioral brain disorders. The company's lead product is SFX-01 that is in Phase II clinical trials for the treatment of metastatic breast cancer; and in Phase I clinical trials for the treatment of neurodevelopmental disorders and glioblastoma, as well as in preclinical stage for the treatment of rhabdomyosarcoma. In addition, it engages in the development of orexin 1 antagonist, which is in late preclinical stage targeting addiction and anxiety; and atypical dopamine transporter inhibitor (DAT), which is in late preclinical stage targeting fatigue and narcolepsy. The company was formerly known as Evgen Pharma plc and changed its name to Theracryf Plc in April 2024. Theracryf Plc was incorporated in 2014 and is headquartered in Nether Alderley, the United Kingdom.

How the Company Makes Money

Evgen Pharma makes money primarily through the development and licensing of its pharmaceutical compounds. The company's revenue model is based on advancing its lead compound, SFX-01, through clinical trials and partnering with larger pharmaceutical companies for commercialization. Revenue streams include potential upfront payments, milestone payments, and royalties from licensing agreements. Additionally, Evgen Pharma may benefit from research grants and collaborations that support its drug development efforts. The company's financial success is closely tied to its ability to progress its compounds through the regulatory approval process and secure strategic partnerships for distribution and marketing.

Evgen Pharma Financial Statement Overview

Summary

Evgen Pharma is facing significant challenges with consistent losses impacting profitability and cash flow. Despite a strong equity position with no debt, the company needs to address its revenue decline and operational losses to ensure long-term sustainability.

Income Statement

The company has shown declining revenue with a negative revenue growth rate of -10.41% year-over-year. The EBIT margin and net profit margin are negative due to ongoing losses, reflecting operational and profitability challenges.

Balance Sheet

The company maintains a strong equity position with no debt, resulting in a solid equity ratio of 76.46%. However, the return on equity is negative due to continuous net losses, highlighting profitability challenges.

Cash Flow

The operating cash flow remains negative, indicating cash burn. However, the free cash flow has improved by 25.65% year-over-year, showing some improvement in cash management.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	396.00K	442.00K	0.00	194.00K
Gross Profit	-866.00K	-2.11M	385.00K	429.00K	-16.00K	-3.19M
EBITDA	-2.15M	-2.06M	-3.55M	-4.99M	-3.15M	-3.19M
Net Income	-2.01M	-1.94M	-3.14M	-4.04M	-2.73M	-2.67M
Balance Sheet
Total Assets	6.62M	7.63M	3.06M	6.17M	9.64M	12.42M
Cash, Cash Equivalents and Short-Term Investments	3.50M	4.11M	2.00M	5.00M	9.03M	11.59M
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00
Total Liabilities	1.82M	1.66M	721.00K	833.00K	411.00K	607.00K
Stockholders Equity	4.80M	5.97M	2.34M	5.34M	9.23M	11.81M
Cash Flow
Free Cash Flow	-1.68M	-2.37M	-3.00M	-4.03M	-2.56M	-2.93M
Operating Cash Flow	-1.68M	-2.37M	-3.00M	-4.03M	-2.56M	-2.93M
Investing Cash Flow	-1.99M	-2.08M	0.00	4.52M	1.48M	-6.00M
Financing Cash Flow	3.93M	4.55M	0.00	0.00	0.00	10.39M

Evgen Pharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.20
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:TCF, the sentiment is Positive. The current price of 0.2 is below the 20-day moving average (MA) of 0.20, below the 50-day MA of 0.20, and below the 200-day MA of 0.23, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 69.48 is Neutral, neither overbought nor oversold. The STOCH value of 73.68 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:TCF.

Evgen Pharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SCLP	48 Neutral	£121.42M	-8.86	―	―	―	-94.12%
SAR	47 Neutral	£27.61M	-5.93	-202.14%	―	―	23.76%
IMM	46 Neutral	£33.68M	-7.53	-259.88%	―	―	―
TCF	45 Neutral	£4.51M	-1.62	-53.79%	―	―	85.56%
HEMO	43 Neutral	£37.76M	-2.82	-609.30%	―	―	―
VAL	41 Neutral	£2.86M	-0.27	―	―	418.49%	27.86%

Evgen Pharma Corporate Events

TheraCryf Hits Key Manufacturing Milestone for Ox-1 Addiction Candidate

TheraCryf has announced a key manufacturing milestone for Ox-1, its lead orexin-1 blocker being developed as a potential treatment for addictive disorders, successfully scaling up production of the drug substance to 10.6kg with yields above target to support 28-day regulatory toxicology studies in two species. With maximum tolerated dose and dose range-finding work now underway, the company expects these toxicology studies to begin in the first half of 2026 and complete in the third quarter, positioning Ox-1 closer to clinical trial readiness and an associated regulatory submission, while engaging investors through a webinar to highlight recent progress and upcoming value inflection points in 2026.

The most recent analyst rating on (GB:TCF) stock is a Hold with a £0.20 price target. To see the full list of analyst forecasts on Evgen Pharma stock, see the GB:TCF Stock Forecast page.

TheraCryf Announces Progress on Preclinical Fatigue Treatment Program

TheraCryf has announced advancements in its second preclinical program, a dopamine modulator (DAT) targeting mental and cognitive fatigue, which has demonstrated promising results in alleviating fatigue without the side effects of conventional stimulants. With central nervous system-related fatigue linked to various severe conditions and no approved treatments currently available, this breakthrough positions TheraCryf to address a growing market expected to double in size to $2.3 billion by 2033, bringing significant potential value to the company and its stakeholders.

TheraCryf Advances Addiction Treatment Program with Strategic Developments

TheraCryf plc has announced significant progress in its addiction-treatment program, Ox-1, which is on track for regulatory submission by the end of 2026. The company has appointed Pharmaron as its development partner and is scaling up manufacturing to meet regulatory requirements. Financially, TheraCryf reported a post-tax loss of £1.3m, with a cash runway extending to the end of 2026. The addiction market, valued at over $40bn, presents a substantial opportunity for TheraCryf, as the company aims to address the human and economic costs of addiction with its promising treatment.

TheraCryf Advances Ox-1 Program Amidst Addiction Awareness Week

TheraCryf plc announced its support for Addiction Awareness Week 2025, highlighting the significant unmet medical needs in addiction treatment. The company is advancing its Ox-1 orexin-1 blocker program, targeting binge eating disorder and substance use disorders, with manufacturing progressing ahead of schedule and robust patent protection secured. The initiative aims to address the high human and economic costs associated with addiction, with clinic readiness expected by the end of 2026.

TheraCryf Advances Addiction Treatment Program Amidst Awareness Week

TheraCryf plc announced its support for Addiction Awareness Week 2025, highlighting the significant unmet medical needs in addiction treatment. The company is advancing its Ox-1 orexin-1 blocker program aimed at treating binge eating disorder and substance use disorders, with progress in manufacturing and patent protection. This initiative underscores TheraCryf’s commitment to addressing addiction’s human and economic impacts, with plans to achieve clinic readiness by the end of 2026.

TheraCryf plc to Announce Half-Year Results on 3 December 2025

TheraCryf plc announced the release of its half-year results for the period ending 30 September 2025, scheduled for 3 December 2025. A live presentation will be held for existing and potential shareholders, featuring key company executives. This announcement is significant for stakeholders as it provides insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and investor relations.

TheraCryf Achieves Key Milestone in Ox-1 Addiction Program

TheraCryf plc has announced a significant milestone in its Ox-1 addiction program, achieving a 0.5kg scale-up of the compound ahead of schedule, with plans to progress to a 10kg scale-up. This advancement is crucial for upcoming in vivo studies and 28-day toxicology studies, which will inform dosing for future clinical trials. The company is also preparing for a Phase 1 healthy volunteer study by manufacturing human-grade drug products under Good Manufacturing Practice (GMP) standards. These developments are expected to bolster TheraCryf’s position in the brain disorder drug development industry and support its goal of submitting a clinical trial application.

TheraCryf Director Increases Stake, Signaling Confidence in Strategic Direction

TheraCryf plc announced that Northern Standard Limited, a company in which Non-Executive Director Ed Wardle holds a 49% interest, has purchased 7,342,296 ordinary shares of the company. This acquisition increases Mr. Wardle’s interest to 20.01% of the company’s issued ordinary shares, potentially strengthening his influence within the company and signaling confidence in TheraCryf’s strategic direction.